in vitro News and Research

RSS

Insilico Medicine reaches preclinical milestone in MASH drug discovery

Insilico Medicine("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, recently achieved preclinical milestone in its collaboration with Therasid Bioscience, a South Korean based biotechnology company focuses on developing innovative first-in-class drugs for treatment for metabolic dysfunction-associated steatohepatitis (MASH).

25 Feb 2025

Study uncovers novel immune evasion mechanism used by key bacterium in periodontitis

Researchers have identified a new mechanism by which a key bacterium in periodontitis evades the immune system.

24 Feb 2025

ETH Zurich team uncovers mechanism behind microbubble drug delivery

ETH Zurich researchers have investigated how tiny gas bubbles can deliver drugs into cells in a targeted manner using ultrasound.

22 Feb 2025

New photosensitizer shows promise in treating colorectal cancer

Colorectal cancer (CRC) is a highly malignant disease that readily metastasizes to vital organs. Many strategies have been employed for clinical CRC therapy.

22 Feb 2025

New computational tool iDOMO improves prediction of drug synergy

Researchers at the Icahn School of Medicine at Mount Sinai have developed a powerful computational tool, named iDOMO, to improve the prediction of drug synergy and accelerate the development of combination therapies for complex diseases.

22 Feb 2025

AI-driven discovery unveils TNIK inhibition as anti-aging strategy

A groundbreaking study led by researchers at Insilico Medicine has revealed the potential of TNIK inhibition as an innovative anti-aging strategy.

22 Feb 2025

Exploring EGCG's role in protecting against acetaminophen-induced liver injury

Announcing a new publication for Acta Materia Medica journal. Excessive consumption of acetaminophen (APAP) has emerged as the primary culprit behind drug-induced liver injury (DILI), with N-acetylcysteine serving as the principal antidote.

21 Feb 2025

Boston University professor receives grant for preeclampsia drug discovery research

Wendy Kuohung, MD, associate professor of obstetrics & gynecology at Boston University Chobanian & Avedisian School of Medicine, has been awarded a two-year, Discovery Research Grant from March of Dimes.

21 Feb 2025

Can chili peppers improve ADHD symptoms? Scientists explore their gut-brain connection

Chili peppers may influence ADHD symptoms by modulating the gut microbiome, with capsaicin, vitamin C, and omega-3 fatty acids showing potential effects on neurotransmitters and inflammation. However, clinical trials are needed to confirm their efficacy.

20 Feb 2025

CPRIT awards nearly $23 million to MD Anderson for cancer research projects

The University of Texas MD Anderson Cancer Center today was awarded nearly $23 million from the Cancer Prevention and Research Institute of Texas (CPRIT) in support of 20 cancer research projects to advance new breakthroughs in discovery, translational, clinical and prevention science.

20 Feb 2025

Gene editing shows promise for treating trisomy at cellular level

Gene editing techniques may eventually allow trisomy to be treated at the cellular level, according to an in vitro proof-of-concept study.

18 Feb 2025

Innovative photodynamic therapy targets melanoma with light-activated dyes

Melanoma is one of the most aggressive skin cancers, with over 300,000 new cases reported worldwide each year. In Europe, the number of diagnoses has been rising rapidly.

17 Feb 2025

New gut-on-chip model could revolutionize immunotherapy for melanoma

A team of researchers from the European Institute of Oncology and the Politecnico di Milano, coordinated by Luigi Nezi, Team Leader of the Department of Experimental Oncology, European Institute of Oncology, and Marco Rasponi, Full Professor of the Department of Electronics, Informatics and Bioengineering, Politecnico di Milano, have developed a "gut-on-chip" (a miniature model of the human intestine on a chip-sized device) capable of reproducing the main features of intestinal inflammation and of predicting the response of melanoma patients to immunotherapy treatment.

14 Feb 2025

Lack of regulation in sperm donation sparks concerns in Africa

Poor regulation and lack of transparency in Africa's fertility industry leave sperm donors and recipients vulnerable to exploitation and unethical practices, including relatives unwittingly having children together, fertility experts warn.

14 Feb 2025

Interferon pathway activation identified as key driver in OPLL pathogenesis

Ossification of the posterior longitudinal ligament (OPLL) is a progressive spinal disease characterized by ectopic bone formation in the spine, leading to severe neurological symptoms due to spinal cord compression. This condition is more prevalent in Asian countries and has been associated with various genetic and hormonal factors.

14 Feb 2025

Study identifies novel enhancers linked to neuropsychiatric disorders

Neuropsychiatric disorders are becoming increasingly prevalent. Given their complex and multifactorial pathogenesis, there is an urgent need for effective and targeted therapies that can improve patients' quality of life.

13 Feb 2025

Vascular changes in brain trauma could trigger Alzheimer’s development

An increased risk of dementia among individuals exposed to brain trauma, traumatic brain injury, has been known for almost a century.

12 Feb 2025

Gut microbiota key to predicting sensitivity to common food additives

Widely used by the food industry, emulsifiers – a type of food additive – are found in many daily foods (sliced bread, ice creams, crème fraîche, plant milks, etc.).

11 Feb 2025

Gut microbes influence how well cancer patients respond to immunotherapy

Researchers discovered that gut microbiota-derived hexa-acylated LPS enhances the effectiveness of anti-PD-1 cancer immunotherapy, while penta-acylated LPS may suppress immune responses.

11 Feb 2025

Insilico Medicine announces preclinical drug discovery benchmarks from 2021 to 2024

Insilico Medicine ( "Insilico") , a clinical stage generative artificial intelligence (AI)-driven biotechnology company today announced a set of preclinical drug discovery benchmarks from the 22 developmental candidate nominations achieved by its platform from 2021 to 2024.

11 Feb 2025